.png)
.png)
Biotech Showcase™ 2018
BIA's Genomics Panel
Generation Genome and Industrial Strategy: Leveraging UK Leadership in Genomics
Monday 8 January - 14.00 - 14.45, Parc 55, Level 3, Market Street
Recent technology advances and the establishment of the 100,000 Genomes programme by Genomics England have created a platform – and in addition the UK Government’s Life Sciences Sector Deal now highlights the data economy and aging population as two of its Grand Challenges. However it is industry that is developing the medicines, treatments and technologies that will impact patients’ lives. This panel brings together representatives from Genomics England, technology partners, SMEs and the venture community to debate the opportunities and challenges that will shape the growth of the UK’s genomics industry and its impact worldwide.
Free of charge.
Co-sponsored with:
Dr Eliot Forster
Eliot has more than 25 years of experience in the pharmaceutical and biotechnology industry and previously served as Chief Executive Officer of Immunocore from 2015 and prior to that was Chief Executive Officer of the biotechnology companies Creabilis Therapeutics (now Sienna Biopharmaceuticals) and Solace Pharmaceuticals Inc. Other previous roles include Head of Development and Operations for the EU and Asia at Pfizer. Eliot has held a number of non-executive Director roles and is currently non-executive Chairman of Avacta plc. He is an Honorary Visiting Professor of the Pharmacology and Physiology Department at the University of Liverpool, a Board member of OSCHR (Office for Strategic Coordination of Health Research), MedCity and the National Genomics Board. He holds a PhD from University of Liverpool and an MBA from Henley Management College.
Sir John Chisholm
Sir John is a Cambridge graduate who started work in the automobile industry. His career took flight when he founded CAP Scientific Ltd, which grew rapidly to become a core part of the CAP Group plc and subsequently the Sema Group plc of which he was UK Managing Director. He was then asked by the government to take on the transformation of its defence research laboratories into a commercial organisation. In due course these became an internationally successful technology services company and were floated on the LSE as QinetiQ Group plc of which Sir John became Chairman in 2006. At the same time he was asked to take the Chair of the Medical Research Council and in 2009 he also took the Chair of Nesta. Sir John retired from QinetiQ in February 2010. Sir John is a past president of the IET and holds a number of honorary Doctorates and Fellowships, including the Royal Academy of Engineering. He was knighted in 1999.
Professor Joanne Hackett
Joanne is the Chief Commercial Officer at Genomics England (GeL). She has been actively involved in clinical research for over 20 years in North America, Europe and the UK. An accomplished entrepreneur, scientist and strategist, she has experience in the execution and management of complex business transactions, as well as broad business development experience in negotiation, execution and management of hundreds of transactions with pharma, biotech, academia and non-profit organisations. Her expertise in creating connections between industry, academia and the NHS will help inform solutions GeL are currently tackling and support the growth of the UK genomic medicine industry. Genomics England is a company owned by the Department of Health and was set up to deliver the 100,000 Genomes Project. This flagship project will sequence 100,000 whole genomes from NHS patients and their families. The project is focusing on patients with rare diseases, and their families, as well as patients with common cancers.
Anthony Finbow
Anthony Finbow is Chief Evangelist at Eagle Genomics, a pioneer in the application of network science to biology across key industries such as Food & Nutrition, Beauty & Personal Care, AgBio and BioPharma. He has worked for over two decades as a leader, building and scaling deep technology businesses, and has a particular enthusiasm for businesses operating at the intersection of life science and data science. Anthony is currently Vice Chairman of the BIA's Genomics Advisory Committee. He is also on the Executive Committee of the UK Knowledge Transfer Network (KTN) Microbiome Innovation Network, set up to develop a proactive, self-sustaining microbiome community in the UK and to raise the visibility of the UK’s world leading microbiome science. As Executive Chairman and CEO, Anthony has built and exited a number of intellectual property rich B2B software companies. In particular, he was responsible for the turnaround, strategic repositioning and sale of private venture backed communications software company, Psytechnics to US Nasdaq-listed NetScout. Similarly, as Managing Director of MetaSolv, he was responsible for doubling the size of the European business, prior to that company being acquired by Oracle. In his early career, Anthony worked as an aircraft engineer and in industrial lasers and electro-optics. He trained as a lawyer and worked as a banker in the privatization of former East German industrial companies, before moving into leadership roles with technology businesses.
Professor Nick Lench
Nick was previously Director of the NE Thames Regional Genetics Service at Great Ormond Street Hospital for Children, with responsibility for the strategic and operational management of a genetics service that provides DNA diagnostic testing to a population of approximately 4.5M people. Nick is an honorary Reader at the UCL Institute of Child Health, and has over 25 years of research experience in human molecular genetics. He was awarded a personal chair in Medical Genetics at Cardiff University in 2005 and is a founding CEO of London Genetics Ltd and Programme Director at Oxagen Ltd.
Michael Stocum
In his 25-year industry career, Michael has impacted products across several therapeutic areas. He has held corporate roles in pharmaceuticals with GlaxoWellcome/GSK, biologics at Organon (now Merck) and molecular diagnostics at Organon Teknika (now bioMerieux) plus two biotech start-ups. His roles have spanned bench research to product, business and commercial development, delivering or enhancing multiple innovative molecular diagnostics. In 2004 Michael founded Personalized Medicine Partners to provide global strategic business and operational capabilities for biopharmaceutical, diagnostic and research/clinical services companies, specialising in product development and commercialisation of integrated therapeutic and biomarker/companion diagnostic programmes. Michael is the founding and past chair of the Personalized Medicine Division of the American Association for Clinical Chemistry and is active in the Personalized Medicine Coalition, a non-profit dedicated to advancing the field of Personalized Medicine. He also serves on the Industry Advisory Board for the Professional Science Masters program at NC State University (NCSU).
Dr Jason Mellad
Jason is a scientist entrepreneur passionate about translating innovative technologies into better patient outcomes. As CEO and co-founder of Start Codon, a Cambridge based accelerator, he aims to identify and recruit the most disruptive healthcare startups worldwide, seed fund them and leverage the exceptional resources of the Cambridge cluster to de-risk and drive their success. Previously he was CEO of Cambridge Epigenetix and Business Development Manager for Horizon Discovery’s diagnostics division. He also served as an associate at Cambridge Enterprise, the technology transfer office of the University of Cambridge.
UK networking event
Monday 8 January, 19:00 - 21:00, Metropolitan Club, Sutter Street, San Francisco
Join us for an evening of whisky tasting, refreshments and hors d'oeuvres as you connect with US and UK life science companies, organisations, renowned expats, and key opinion leaders from the industry. The event will be held at the Metropolitan Club at 19:00 pm. BIA CEO Steve Bates and Genomics England will give some brief words of greeting. Hosted by he UK's Department for International Trade and Scottish Development International.
Free of charge, but reservations required.
Please RSVP by January 3rd.
About Biotech Showcase™
8 - 10 January 2018, Hilton San Francisco Union Square, USA
Biotech Showcase™ is an investor and partnering conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.
Now in its tenth year, Biotech Showcase 2018 is expected to feature presentations by close to 400 public and private companies and attract more than 3,000 attendees. The event will run a full program of topical plenary sessions and workshops, including special-focus events dedicated to emerging trends.
The demand for innovation in all areas of human health is the impetus behind Digital Medicine & Medtech Showcase, a focus event taking place during Biotech Showcase at Parc 55 in San Francisco.
https://ebdgroup.knect365.com/biotech-showcase/
Watch our webinar:
Organizers:
Demy-Colton Life Science Advisors and EBD Group, Inc.
BIA Member Discount:
$350 discount for BIA members through BioPartner. Please email Alex to get your discount code.
BIA Member Discount:
$300 discount for BIA members through BioPartner.
Please email Alex to get your discount code.